CRISPR Therapeutics AG (CRSP) Financials
Key financial figures for CRISPR Therapeutics AG (Q3 2026).
CASGEVY revenue reached $99 million in Q3 2026, up 30% from Q2 and nearly six times Q3 2025, while the net loss was $111.4 million. CASGEVY generated $99 million of revenue in Q3 2026, up 30% quarter-over-quarter and nearly six times Q3 2025 (company release); more than 750 patients worldwide have initiated treatment. Collaboration revenue was $12.3 million versus none in Q3 2025; collaboration expense, net, fell to $41.3 million from $57.1 million, which the company attributes mainly to its larger share of CASGEVY revenue. Net loss was $111.4 million ($1.15 per diluted share) versus $106.4 million ($1.17) a year earlier; loss from operations was $130.0 million versus $132.1 million. Figures are for Q3 2026, as CRISPR Therapeutics AG reported them.
- Revenue
- $13M
- Net Income
- -$111M
- EPS
- $-1.15
- Total Assets
- $2.6B
- Operating Cash Flow
- -$90M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $13M | -$111M | -$1.15 | -1026.48% | -$90M |
| Q2 FY2026 | $10M | -$91M | -$0.94 | -1127.55% | -$87M |
| Q1 FY2026 | $1M | -$123M | -$1.28 | -8933.33% | -$109M |
| Q4 FY2025 | $864K | -$131M | -$1.37 | -17912.5% | -$93M |
| Q3 FY2025 | $889K | -$106M | -$1.17 | -14854.78% | -$85M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $4M | -$582M | -$6.47 | -16191.4% | -$346M |
| FY2024 | $35M | -$366M | -$4.34 | -1333.05% | -$145M |
| FY2023 | $370M | -$154M | -$1.94 | -60.15% | -$270M |
Frequently asked questions
What was CRISPR Therapeutics AG's revenue last quarter?
CRISPR Therapeutics AG reported revenue of $12.7 million for Q3 FY2026, up 1325.1% from the same period a year earlier.
Is CRISPR Therapeutics AG profitable?
Not in its most recent reported period. CRISPR Therapeutics AG reported a net loss of $111.4 million for Q3 FY2026, a net margin of -879.6% on revenue.
How has CRISPR Therapeutics AG's margin trended?
Operating margin was -1026.48% in Q3 FY2026, compared with -14854.78% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did CRISPR Therapeutics AG generate?
CRISPR Therapeutics AG generated free cash flow of -$90.1 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for CRISPR Therapeutics AG on SentiSense, with up to forty quarters and twenty fiscal years of history.